<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927341</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2116</org_study_id>
    <secondary_id>2013-001986-18</secondary_id>
    <nct_id>NCT01927341</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors</brief_title>
  <official_title>A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to
      assess the anti-tumor activity of MEK162 in combination with panitumumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities in cycle 1 (Phase Ib)</measure>
    <time_frame>6 months</time_frame>
    <description>Estimation of maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response rate (Phase II)</measure>
    <time_frame>one year</time_frame>
    <description>Assess clinical efficacy as per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>one year</time_frame>
    <description>Frequency and severity of AEs, SAEs, changes in laboratory values, vital signs, and electrocardiograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (Phase lb)</measure>
    <time_frame>one year</time_frame>
    <description>Assess preliminary anti-tumor activity as per RECIST 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free- survival</measure>
    <time_frame>one year</time_frame>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>one year</time_frame>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>one year</time_frame>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: Dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Patients with mutant RAS mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Patients with acquired mutant RAS mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (pretreated)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (not pretreated)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>Tablet for oral use, 15 mg, BID</description>
    <arm_group_label>Phase Ib: Dose escalation</arm_group_label>
    <arm_group_label>Phase II: Patients with mutant RAS mCRC</arm_group_label>
    <arm_group_label>Phase II: Patients with acquired mutant RAS mCRC</arm_group_label>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (pretreated)</arm_group_label>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (not pretreated)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)</description>
    <arm_group_label>Phase Ib: Dose escalation</arm_group_label>
    <arm_group_label>Phase II: Patients with mutant RAS mCRC</arm_group_label>
    <arm_group_label>Phase II: Patients with acquired mutant RAS mCRC</arm_group_label>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (pretreated)</arm_group_label>
    <arm_group_label>Phase II: Patients with WT RAS mCRC (not pretreated)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Metastatic colorectal cancer

          -  Progression on or following standard therapy, or no standard therapy (phase Ib).
             Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy
             regimens (phase II)

          -  Written documentation of mutant or wild-type RAS

          -  Life expectancy ≥ 3 months

          -  ECOG performance status ≤ 2

        Exclusion Criteria:

        Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other
        EGFR inhibitors

          -  Previous treatment with MEK-inhibitors

          -  History of severe infusion reactions to monoclonal antibodies.

          -  Symptomatic or untreated leptomeningeal disease

          -  Symptomatic brain metastasis

          -  Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as assessed
             by ophthalmologic examination at baseline that would be considered a risk factor for
             CSR/RVO and history of keratitis.

          -  Acute or chronic pancreatitis

          -  Clinically significant cardiac disease

          -  Not adequate hematologic, renal and hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles Dept of Onc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Oncology Dept</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <disposition_first_submitted>February 11, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 11, 2016</disposition_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEK162,</keyword>
  <keyword>panitumumab,</keyword>
  <keyword>mutant RAS,</keyword>
  <keyword>wild-type RAS,</keyword>
  <keyword>metastatic colorectal cancer,</keyword>
  <keyword>adult mCRC patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

